This study is aimed at investigating tumoral and inflammatory cells and the significance of the prognostic factors of pancreatic ductal adenocarcinoma (PDAC); it is also aimed at determining the role of immunohistochemistry in the diagnosis and prognosis of this neoplasm. Materials and Methods. 230 cases of pancreatic ductal adenocarcinoma were included in the study group; these cases were selected from the archives of the Department of Pathology of the Fundeni Clinical Institute over a ten-year period. Immunohistochemistry was performed using the following antibodies: MUC 1, CD 34, Factor VIII, CD 68, MMP-7, CEA, p21, p53, and Ki 67. Results. There were 133 male (57.8%) and 97 female (42.2%) patients included in this study, with ages between 20 and 81 years old (mean age: 58.2 years) and with tumors located in the pancreatic head (; 85.2%), pancreatic body (; 5.2%), and pancreatic tail (, 8.7%), as well as panpancreatic tumors (; 0.9%). Patients presented with early stages (IA and IB), with low pathologic grade (G1), with small size tumors (less than 1-1.5 cm), with tumors located in the head of the pancreas, (p53: negative; p21: positive; and CD 68: positive in peritumoral tissue), with low nuclear index (), without metastases at the time of surgery (had a better prognosis), and with a survival rate of about 7 months. Conclusions. Immunohistochemistry is useful for an accurate diagnosis, differential diagnosis, and establishment of additional factors that might have a prognostic importance. It is recommended to study peritumoral tissue from the quantitative and qualitative points of view to increase the number of prognostic factors. This study represents a multidisciplinary approach, and it is a result of teamwork; it presents histopathological methods of examination of this severe illness and describes only a part of the scientific effort to determine the main pathological mechanisms of this neoplasm.

中文翻译：

---

胰腺导管腺癌的肿瘤细胞和炎症细胞的形态学和免疫组织化学研究

这项研究旨在调查肿瘤和炎症细胞以及胰腺导管腺癌（PDAC）的预后因素的意义。它还旨在确定免疫组织化学在该肿瘤的诊断和预后中的作用。材料和方法。研究组包括230例胰腺导管腺癌。这些病例是在十年期间从Fundeni临床研究所病理学系的档案中选出的。MUC 1，CD 34，因子VIII，CD 68，MMP-7，CEA，P21，P53，和Ki 67免疫组化用下列抗体进行结果。这项研究纳入了133例男性患者（57.8％）和97例女性患者（42.2％），年龄在20至81岁之间（平均年龄：58.2岁），并且肿瘤位于胰头（; 85.2％），胰体（; 5.2％）和胰尾巴（（ 8.7％）以及胰腺肿瘤（; 0.9％）。处于早期阶段（IA和IB），病理分级（G1）低，肿瘤小（小于1-1.5 cm），肿瘤位于胰头的患者（p53：阴性; p21：阳性） ；和CD 68：在肿瘤周围组织中呈阳性），核指数低（），手术时无转移（预后较好），生存率约为7个月。结论。免疫组织化学可用于准确诊断，鉴别诊断和建立可能具有预后意义的其他因素。建议从定量和定性的角度研究肿瘤周围组织，以增加预后因素。这项研究代表了一种多学科的方法，是团队合作的结果。它介绍了检查这种严重疾病的组织病理学方法，并且仅描述了确定该肿瘤主要病理机制的科学工作的一部分。